Skip to content
BiologicalX

Comparison

Hexarelin vs Methylene Blue

Side-by-side of Hexarelin and Methylene Blue. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Hexarelin

  • Synthetic hexapeptide GHS-R1a agonist; produces the largest acute GH pulse of the synthetic GHRP class
  • Independent CD36 signaling produces cardioprotective effects in rodent ischemia models, GH-independent
  • Pronounced tachyphylaxis: GH response attenuates over 2 to 4 weeks of daily dosing
  • More cortisol and prolactin elevation than GHRP-2 or ipamorelin
  • Anecdotal protocols use 100 to 200 mcg subcutaneously 1 to 2 times daily for 2 to 4 week pulses
  • Banned by WADA under S2; advanced through phase 2 trials but never reached registration

Methylene Blue

  • FDA approved for methemoglobinemia and ifosfamide-induced encephalopathy
  • Mitochondrial electron-transport support at low doses (0.5 to 4 mg/kg) via cytochrome c shuttle
  • Potent MAO-A inhibitor; serotonin syndrome risk with SSRIs, SNRIs, MAOIs, fentanyl, tramadol, St John's wort
  • Causes harmless blue-green urine and sweat coloration; useful adherence marker
  • G6PD deficiency is an absolute contraindication; can trigger massive hemolysis
  • Cognitive-enhancement evidence is preliminary, mostly preclinical and small fMRI trials

Side-by-side

Attribute Hexarelin Methylene Blue
Category peptide pharmaceutical
Also known as Examorelin, EP-23905, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 Methylthioninium chloride, Provayblue, tetramethylthionine chloride
Half-life (hr) 1 5.5
Typical dose (mg) 0.1 70
Dosing frequency 1-2x daily 1 to 3 times daily for cognitive use; single IV dose for methemoglobinemia
Routes subcutaneous, intranasal, intravenous oral, intravenous
Onset (hr) 0.25 1
Peak (hr) 0.5 1.5
Molecular weight 887.04 319.85
Molecular formula C47H58N12O6 C16H18ClN3S
Mechanism Hexapeptide agonist of GHS-R1a producing acute GH release with cortisol and prolactin co-elevation. Independent CD36 binding produces GH-independent cardioprotective signaling in preclinical models. Mitochondrial electron carrier at low doses (cytochrome c shuttle to complex IV) and methemoglobin reductase substrate at higher doses; potent MAO-A inhibitor across the dose range.
Legal status Not FDA approved; advanced through phase 2 trials in EU but never registered; research-use-only grey market; banned by WADA Prescription (injectable, FDA approved); supplement form (oral) widely available; not scheduled
WADA status banned allowed
DEA / Rx Not scheduled (research chemical) Not scheduled in the US
Pregnancy Insufficient data; not recommended Contraindicated
CAS 140703-51-1 61-73-4
PubChem CID 3037387 6099
Wikidata Q5743550 Q409021

Safety profile

Hexarelin

Common side effects

  • water retention
  • vivid dreams
  • head pressure or flushing
  • transient lethargy
  • tingling at injection site
  • moderate hunger

Contraindications

  • pregnancy
  • active malignancy
  • history of pituitary tumor
  • uncontrolled diabetes
  • prolactin-sensitive states

Interactions

  • CJC-1295: synergistic GH release; accelerates tachyphylaxis if used continuously(minor)
  • sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
  • insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
  • corticosteroids: amplify cortisol load; blunt GH response(moderate)

Methylene Blue

Common side effects

  • blue-green urine and sweat
  • skin and oral mucosa staining
  • GI upset
  • headache
  • dizziness

Contraindications

  • G6PD deficiency
  • pregnancy
  • concurrent serotonergic medication
  • severe renal impairment
  • infants under 6 months

Interactions

  • SSRIs and SNRIs: serotonin syndrome, potentially fatal(major)
  • MAOIs: additive MAO inhibition, serotonin syndrome risk(major)
  • fentanyl, tramadol, meperidine: serotonin syndrome risk(major)
  • dextromethorphan: serotonin syndrome risk(major)
  • St John's wort: serotonin syndrome risk(major)
  • lithium: additive serotonergic risk(major)

Which Should You Take?

Methylene Blue comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. Hexarelin is the right call when one of the conditionals below applies.

  • If your priority is growth-hormone axis, pick Hexarelin.
  • If your priority is post-training recovery, pick Hexarelin.
  • If your priority is focus or working memory, pick Methylene Blue.
  • If your priority is mitochondrial function, pick Methylene Blue.

Edge case: If you cannot self-administer injections, Methylene Blue is the only oral option in this pair.

Default choice: Methylene Blue. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Hexarelin only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Hexarelin and Methylene Blue?

Hexarelin and Methylene Blue differ in category (peptide vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Hexarelin or Methylene Blue?

Hexarelin half-life is 1 hours; Methylene Blue half-life is 5.5 hours.

Can you stack Hexarelin with Methylene Blue?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper